$599

Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics

January 31, 2025

Novartis and Biocon Q4 ’24 Earnings; Metsera and Beta Bionics IPO Updates; Fractyl Business Updates

A series of cardiometabolic-related news items have been observed by Novartis, Metsera, Beta Bionics, Biocon, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Return to Home